Kenichi Inoue Selected Research

orantinib (SU6668)

1/2014	A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.
8/2013	A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenichi Inoue Research Topics

Disease

85	Breast Neoplasms (Breast Cancer) 05/2024 - 01/2002
34	Neoplasms (Cancer) 01/2023 - 01/2006
11	Neutropenia 09/2021 - 01/2006
9	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2007
8	Triple Negative Breast Neoplasms 10/2023 - 03/2011
7	Disease Progression 10/2023 - 01/2010
7	Diarrhea 09/2021 - 01/2013
7	Nausea 02/2019 - 02/2009
6	Vomiting 02/2019 - 02/2009
5	Leukopenia 09/2021 - 01/2006
3	Peripheral Nervous System Diseases (PNS Diseases) 10/2020 - 08/2013
3	Pain (Aches) 01/2018 - 07/2011
3	Fatigue 09/2017 - 02/2016
2	Lung Neoplasms (Lung Cancer) 01/2020 - 02/2016
2	Hyperglycemia 01/2019 - 09/2012
2	Alopecia (Baldness) 06/2018 - 12/2015
2	Febrile Neutropenia 08/2017 - 10/2006
2	Constipation 01/2013 - 02/2009
2	Body Weight (Weight, Body) 09/2012 - 10/2009
2	Margins of Excision 03/2010 - 08/2009
2	Ductal Carcinoma 01/2007 - 07/2003
1	Obesity 04/2024
1	Overweight 04/2024
1	Thrombosis (Thrombus) 01/2024
1	Ulcerative Colitis 01/2024
1	Weight Loss (Weight Reduction) 11/2023
1	Osteoporosis 11/2023
1	Brain Neoplasms (Brain Tumor) 10/2023
1	Neurodevelopmental Disorders 01/2022

Drug/Important Bio-Agent (IBA)

20	Hormones (Hormone)IBA 10/2023 - 01/2007
19	Trastuzumab (Herceptin)FDA Link 05/2024 - 01/2006
18	ErbB Receptors (EGF Receptor)IBA 10/2023 - 01/2010
16	Estrogen ReceptorsIBA 09/2021 - 09/2006
13	Paclitaxel (Taxol)FDA LinkGeneric 08/2021 - 08/2003
9	AnthracyclinesIBA 01/2020 - 02/2009
9	Docetaxel (Taxotere)FDA Link 05/2017 - 01/2006
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2017 - 02/2009
8	palbociclibIBA 10/2023 - 08/2017
8	Fulvestrant (Faslodex)FDA Link 11/2021 - 08/2017
8	human ERBB2 proteinIBA 10/2020 - 04/2011
6	eribulin FDA Link 07/2021 - 01/2016
6	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 01/2007
5	abemaciclibIBA 11/2021 - 09/2017
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 08/2013
5	neratinibIBA 01/2021 - 12/2016
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2011
5	taxaneIBA 03/2017 - 03/2011
4	Lapatinib (GW572016)FDA Link 08/2021 - 05/2013
4	Palonosetron (Aloxi)FDA Link 02/2019 - 02/2009
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016 - 01/2010
4	Epirubicin (Ellence)FDA LinkGeneric 01/2016 - 05/2013
3	Letrozole (Femara)FDA LinkGeneric 10/2023 - 03/2018
3	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 02/2009
3	exemestane (Aromasin)FDA Link 09/2021 - 01/2008
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2013
3	pertuzumabIBA 02/2020 - 01/2019
3	Taxoids (Taxanes)IBA 01/2020 - 03/2011
3	130-nm albumin-bound paclitaxelIBA 12/2019 - 08/2013
3	Indicators and Reagents (Reagents)IBA 01/2018 - 01/2017
3	Aromatase InhibitorsIBA 01/2018 - 04/2011
3	Fluorouracil (Carac)FDA LinkGeneric 09/2015 - 05/2013
3	Tamoxifen FDA LinkGeneric 12/2014 - 04/2011
2	LigandsIBA 01/2023 - 12/2017
2	Neurokinin-1 Receptor AntagonistsIBA 01/2022 - 02/2019
2	Amino Acids FDA Link 01/2020 - 02/2016
2	atezolizumabIBA 01/2020 - 12/2019
2	B7-H1 AntigenIBA 12/2019 - 11/2019
2	Messenger RNA (mRNA)IBA 06/2019 - 08/2013
2	Cyclin-Dependent Kinase 4IBA 01/2019 - 09/2017
2	Bevacizumab (Avastin)FDA Link 06/2018 - 01/2017
2	Granisetron (Kytril)FDA LinkGeneric 01/2016 - 02/2009
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2016 - 02/2009
2	Hemoglobins (Hemoglobin)IBA 12/2015 - 10/2006
2	orantinib (SU6668)IBA 01/2014 - 08/2013
2	Oxycodone (Oxycontin)FDA LinkGeneric 08/2013 - 07/2011
2	SandIBA 10/2009 - 05/2008
2	Coloring Agents (Dyes)IBA 01/2006 - 01/2006
1	Chalcone (Benzalacetophenone)IBA 04/2024
1	xanthoangelolIBA 04/2024
1	AntibodiesIBA 01/2024
1	AutoantibodiesIBA 01/2024
1	diphosphoric acid (pyrophosphoric acid)IBA 11/2023
1	Phosphates (Orthophosphate)IBA 11/2023
1	trastuzumab deruxtecanIBA 10/2023
1	patritumab deruxtecanIBA 10/2023
1	Immunoconjugates (Immunoconjugate)IBA 10/2023
1	pembrolizumabIBA 01/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2022
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 11/2022
1	talazoparibIBA 11/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2022

Therapy/Procedure

43	Therapeutics 01/2024 - 01/2002
22	Drug Therapy (Chemotherapy) 01/2023 - 10/2006
11	Neoadjuvant Therapy 01/2020 - 01/2007
7	Adjuvant Chemotherapy 01/2020 - 07/2003
4	Radiotherapy 05/2015 - 09/2006
4	Lymph Node Excision (Lymph Node Dissection) 01/2010 - 01/2007
3	Segmental Mastectomy (Lumpectomy) 06/2013 - 08/2009
2	Duration of Therapy 09/2021 - 01/2019
2	Mastectomy (Mammectomy) 05/2015 - 04/2011